Non-small cell lung cancer
Conditions
Interventions
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Non-squamous non-small cell lung cancer patients: a) newly diagnosed untreated non-resectable late-stage (IIIB or IV) patients with ALK fusion-positive confirmed by histology or cytology; b) or ALK fusion-positive patients with ALK inhibitor failure, without further treatment yet (2) Fresh tissue or FFPE specimens were negative of sensitive mutations of EGFR detected by DNA sequencing or ARMS; (3) The subjects understand and voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: (1) Pathologically confirmed squamous cell carcinoma, or mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinoma with squamous cells as the primary component; (2) Patients who do not provide sufficient tissue or cells for EGFR and ALK genotyping; patients with positive EGFR mutations; patients with negative ALK fusion mutations; (3) Coagulopathy (PT time > 2 times the upper limit of normal or PLT < 50X10^9/L).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALK fusion; | — |
Countries
China
Contacts
Public ContactJun Zhao
Department of Thoracic Oncology, Beijing Cancer Hospital
Outcome results
None listed